Small molecule MIF antagonist CPSI-1306 treatment in a mouse model with streptozotocin (STZ)-induced T2D, resulted in reduced circulating IL-6 and TNF-α levels and reduced blood glucose levels (Sanchez-Zamora et al., 2010). This evidence concerns the gene TNF and type 2 diabetes mellitus.